---
title: "Advancements in Bladder Cancer Treatment: Insights from the SURE-02 Trial"
id: "news-news-lancet-oncology-68c6cfd3025fe192f324ab58"
canonical_url: "https://medichelpline.com/news/news-news-lancet-oncology-68c6cfd3025fe192f324ab58"
content_type: "medical_news_article"
category: "Oncology"
source_name: "The Lancet Oncology"
source_url: "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00073-2/fulltext?rss=yes"
published_at: "2026-02-27T20:00:01.000Z"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Advancements in Bladder Cancer Treatment: Insights from the SURE-02 Trial
## Metadata & Source Attribution
- **Canonical URL:** https://medichelpline.com/news/news-news-lancet-oncology-68c6cfd3025fe192f324ab58
- **Category:** [Oncology](https://medichelpline.com/news/oncology.md)
- **Reporting Source:** The Lancet Oncology
- **Original Source URL:** [Read Original Article](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00073-2/fulltext?rss=yes)
- **Published At:** 2026-02-27T20:00:01.000Z
## Executive Summary & Key Highlights
Recent trials have changed treatment approaches for muscle-invasive bladder cancer, incorporating immune checkpoint inhibitors alongside traditional therapies.
## In-Depth Reporting & Editorial Analysis
Neoadjuvant therapy based on cisplatin has traditionally been the standard treatment for muscle-invasive bladder cancer. Over the last five years, several significant trials have facilitated the integration of immune checkpoint inhibitors into this treatment paradigm. Notably, the phase 3 NIAGARA trial resulted in the approval of durvalumab when used in conjunction with gemcitabine or cisplatin, followed by adjuvant monotherapy with immune checkpoint inhibitors. Furthermore, the CheckMate-274 and AMBASSADOR trials highlighted enhanced outcomes for those receiving these adjuvant therapies.
## Navigation
- [← Back to Oncology News](https://medichelpline.com/news/oncology.md)
- [← All Medical News Categories](https://medichelpline.com/news.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.